Connect with us

Markets and industry

CanCoin: a FinTech solution for the European cannabis industry 

The CanCoin is developing an entire ecosystem around the token in a bid to revolutionise the European cannabis market.

Published

on

CanCoin: a FinTech solution for the European cannabis industry 

The newly launched cannabis industry token, The CanCoin, is developing an entire ecosystem around the token in a bid to revolutionise the European cannabis market.

The legal European cannabis market is estimated to reach $70bn by 2025, but the emerging industry still faces barriers that are hindering its full potential, such as financial institutions’ reluctance to serve domestic companies, traceability, privacy and costly operations. To add to the problem, despite changing legislation at national levels, there remains a lack of a harmonised regulatory framework across the continent. 

Launched by leading DeFi advisory group Technicorum Holdings, specialising in digital assets, European crowdfunding expert Daniel Daboczy, as well as David Bonnier and Amaury de Poret, co-founders and investment managers of Enexis AB, The CanCoin sets itself apart as an innovative solution with high potential for this nascent industry.

A FinTech solution

The CanCoin’s white paper details how it aims to penetrate the market by offering tools to companies across the cannabis value chain, including track and trace solutions, a decentralised payment network, crowdfunding capabilities, secure patient data, NFTs, and a rapid coin adoption strategy. 

CEO Daniel Daboczy said: “The coin itself is one product and then we also aim to solve certain issues in the industry. We want a lot of people in the industry to use the coin. So, right now – the pound, the euro, the dollar, the yuan, they are vertical coins – one purpose fits all and some people benefit a lot, for instance, financial institutions and banks, and some private citizens do not benefit at all by using a certain currency over the other. What a lot of people think is that the currency system, which is from the 1600s, is a bit obsolete at this point. There are a lot of people in vertical coins – real estate coins for the real estate industry, influencer coins for the influencer industry, cannabis coins for the cannabis industry. So, that is what we are aiming towards, but, it is not only people in the cannabis business that can use it, it could be used by anybody, as any cryptocurrency can be. So, it can be used for purchasing, traceability, or speculation, for example.

“If you look at the US, Amazon gift cards are the preferred currency right now in a lot of purchases, which is absurd. Then, you cannot transport money between states in the US, you cannot bank the cash. Those are major, major issues for the industry. Why go through all the hassle when you can pay through a cryptocurrency. Right now you could use Bitcoin in theory, or whichever cryptocurrency you can use already, but there are some problems with that. 

“We want to create an industry token, and then eventually a blockchain, which also adds traceability and trust to the system, thus, eventually, leading to legislation. Legislation can only happen if governmental bodies and the legislative bodies feel that they can trust this. They will never approve some kind of a grey-zone, libertarian type of thing, but a proper FinTech solution is welcomed by many people.” 

Alongside the coin, the blockchain that will be developed will allow for transparent and trustworthy documentation of any item, smart contracts, and will enable the replacement of paper trails. Customers will also be able to check information on their products such as origin, third-party testing and expiration date, for example. 

Backed by experts

The CanCoin is supported by leading experts in DeFi, cannabis, finance and funding. Singapore-based Technicorum Holdings is one of the world’s leading crypto advisors, and Daboczy has a strong background in the FinTech industry, having co-founded the international crowdfunding platform FundedByMe. Additionally, team members David Bonnier and Amaury de Poret are the co-founders and investment managers of Enexis AB, one of the first cannabis investment companies in Europe. It also has a group of “secret” advisors who offer their expertise in blockchain and pharma. 

“Our secret advisors are people who are giving us advice, especially on the blockchain bill, and we have advisors who are from the pharmacy industry in the EU,” said Daboczy. “These people are already giving us advice on how the pharmacy industry is working, and we have some people who understand the cannabis industry is growing, and they also understand that the crypto industry is growing. But, they can’t put the names there because their employer might frown or, because not everybody understands that you don’t have to be a cannabis smoker to do FinTech for the industry.”

Tech, media and Pharma expert Scott de Maercado was recently appointed to The CanCoin Advisory Board, which includes crypto expert and advisor Malcolm Tan, and cannabis industry expert, Jonas Saeed. The CanCoin is also collaborating with Massfluencer, a data-driven marketing company, Cryptologicals, crypto and financial marketing and content specialists, and Transform Group, a globally leading blockchain communications company.

“Our team has got several successful startups, and my platform helped over 650 companies successfully get fundraising. We have learned what works and doesn’t work, and having a clean and clear path is important,” added Daboczy.

“We understand how to build a company, how to work with the political parties and the legislative bodies, and how to build good tech and make sure that you have a user base, those three elements are very important for these products.”

Creating an ecosystem

As well as crowdfunding capabilities, payment solutions, DNA storage and patient data, The CanCoin will be creating Augmented Reality NFT’s, allowing users to grow their own cannabis plants and earn CanCoin.

Daboczy said: “The NFT industry truly exploded earlier this year, and it has mainly been artists, musicians and filmmakers who realised that Corona hit them really hard. My background is also in the art scene, I was curator for many years and I’ve done many successful exhibitions. NFT’s are basically an emancipator for the creative industry to do several things – to bypass gatekeepers, and to create different packaging solutions, for example.

“Right now, an artist has to sell a finished product, or a finished song or a finished art piece, decided by somebody else who can sell it. I would want to package an idea. So, our NFTs will serve several purposes – to engage people to see other values than just a coin and the other, which is very important, is gamification. Users will be able to work for our purposes – we give you certain tasks to fulfill, and we pay you coins once you reach them. It becomes almost like a simple app game, but with a purpose to engage. We want to add the gamified element to the art element.”

Revolutionising the industry

Daboczy says The CanCoin aims to become a central bank for the European Cannabis industry, and believes that the project has the scalability to succeed.

“We want to get to a point where the banks are allowing cash deposits or transactions in this field, which is currently a minefield. As soon as you change banks or you go from a major city to a smaller city – if you are working country by country or in a cross-border transaction, it is almost impossible to bank in this industry. Not everybody has good fortune with their banking system. 

“So, we want to use the banking system, as much as possible. At the end of the day, if we do this correctly and if we succeed according to our ambitions and plans, we will become a central bank for this industry. We will have the tools, we will have the currency, we will have the technology, and we will have the establishment – that is our aim.

“The blockchain is one of the best inventions of the last decade. A blockchain has a purpose to show traceability. The first simplest traceability is patient traceability. The legislative bodies cannot legalise something that is not traceable. We believe that adding certain elements of traceability will add to the usage. Do I believe that the blockchain will solve any and every issue of the cannabis industry, most likely not. Will everybody be on this blockchain, most likely not. Not in the next years, but eventually, everybody’s got to be on it – I’m comparing crypto to the internet in 1996. Not everybody could grasp what it could become, or what it would become in 25 years.

“This is the same issue that we have here. Eventually, industry will catch up and eventually the tools established or demanded by the government bodies will be used. I think somebody has to do it right and I think we have the right background to do a proper and solid attempt. It’s all about doing it differently, better and a lot more scalable. A lot of the medical industry is digitalised or partially digitalised. The blockchain is even more advanced than the solutions we have in Sweden or the UK at this point. 

“The blockchain industry is growing extremely fast and over the next 10 years is going to be atomic. It is the same with the legal cannabis industry and also the entire cannabis industry globally in the next seven years, major leaps will happen.”

The CanCoin is currently in the presale period with 22 August expected as the minting date. It is expected to list on a number of decentralised exchanges, starting with KingSwap, and will potentially list on at least one centralised exchange at the end of October. 

Daboczy says The CanCoin may eventually be tethered to the Euro or the US dollar, as not everybody in the industry will want to use a volatile currency. The CanCoin will be making offerings and holding gamified events until the coin is listed, which Daboczy says will be at around 17 cent per coin.  

Markets and industry

Panaxia to expand its Malta production plant with $6m investment

Panaxia’s investment in the country is a “milestone” for Malta’s medical cannabis industry, says Minister for the Environment, Energy and Enterprise.

Published

on

Panaxia to expand its Malta production plant with $6m investment
Home » News » Markets and industry » CanCoin: a FinTech solution for the European cannabis industry 

Israel-based Panaxia is set to expand its medical cannabis production facility in Malta and will export its first products to Germany in the coming weeks.

Panaxia is set to deepen its connection with Malta as it plans a further expansion to its local production plant now the company has obtained its EU-GMP licence. 

The company received an official license from the health authorities in Malta to manufacture finished medical cannabis products in May, 2022.

The news of Panaxia’s $6m (~£4.95m) investment was announced during a visit to Panaxia’s Ħal Far plant by Malta’s Minister for the Environment, Energy and Enterprise Miriam Dalli. 

Read more: Panaxia to exit cannabis activities in Israel and focus on Europe

Panaxia aims to enrich the Maltese production portfolio with products aimed for both Europe and Latin American markets. To do this, its Malta facility will diversify into an array of products ranging from the production of tablets, oil and extracts, as well as carrying out clinical trials, stability experiments and research and development.

Minister Miriam Dalli described Panaxia as an early success story for one of Malta’s newest economic niches.

Read more: Panaxia to begin medical cannabis production in Malta

Minister Dalli commented: “Malta Enterprise has been in discussions with Panaxia since the early days after the enacted legislation in 2018. Today, Panaxia is only marking the start of its actual production, but it is already planning an expansion in its facilities. 

“This is another milestone reached for our medical cannabis industry – an industry which further enriches our wider pharmaceutical sector. Malta is the ideal location for such operations, whereby specialised products are developed for the global healthcare supply chain.”

CEO of Panaxia, Dadi Segal, commented: “I am impressed with the role of Malta Enterprise in their support to our Malta team at Panaxia on various levels, not just the financial assistance but also the constant communication and facilitation. 

“We had to build this facility from scratch and the process was long but soothed through Malta Enterprise’s constant guidance.”

Panaxia also operates from locations within the United States, Canada and South Africa, and is currently in the process of registering products in Portugal, Greece, Poland and Brazil amongst others. Its range of pharmaceutical products, over 60 in all, are mainly based on cannabis plant extracts and treat a variety of ailments including nausea, anxiety and depression.

Continue Reading

Markets and industry

Cannabis extract registered in Poland by Curaleaf International

The landmark registration signifies Curaleaf’s continued expansion into Europe.

Published

on

Cannabis extract registered in Poland by Curaleaf International
Home » News » Markets and industry » CanCoin: a FinTech solution for the European cannabis industry 

Curaleaf International has registered its cannabis-based medical extract in Poland with local partner CanPoland SA.

Curaleaf International’s product registration in Poland will help to meet increasing demand for cannabis medicine in the country. According to Prohibition Partners, Poland is currently one of Europe’s largest medical cannabis markets by patient size. Its market is expected to reach €2bn (~£1.69bn) by 20282. 

Read more: Can4Med to wholesale medical cannabis products in Poland

The licensed product, which is 100 per cent European sourced from plant to manufacture, is part of Curaleaf International’s proprietary product range that has now launched in five key European markets, including the UK and Germany.

Curaleaf International president, Miles Worne, stated: “This licence in Poland is another sign of Curaleaf International’s strong momentum in Europe. The medical cannabis market in Europe continues to expand rapidly, as regulation opens up and access for patients improves. 

Read more: Curaleaf partnership to build platform for German recreational market

“Since the legalisation of medical cannabis in 2017, Poland has become one of the largest European importers of dried flower and is an excellent addition to Curaleaf International’s expansion, given its fast-growing patient numbers and significant addressable market.

“Curaleaf International is driving growth in existing key markets, with the UK in particular witnessing a huge increase in patient numbers, whilst continuing to drive expansion into new markets across Europe.”

Curaleaf International has also recently announced registrations of products in Malta, and was the first company to register a THC cannabis extract Active Pharmaceutical Ingredient in Italy. 

The company has stated that this news, along with the opening of the Swiss medical cannabis market and Curaleaf International’s renewing of its GDP licence in Switzerland, is an example of where the company is ideally positioned to capitalise on positive market movements across Europe.

Continue Reading

Markets and industry

Medcolcanna signs European medical cannabis sales agreements

The company has entered into sales agreements with German company, Greenstein, and Cantourage.

Published

on

Medcolcanna signs European medical cannabis sales agreements
Home » News » Markets and industry » CanCoin: a FinTech solution for the European cannabis industry 

Canada-based globally integrated medicinal cannabis company with operations in Colombia, Medcolcanna, has signed two EU sales agreements for EU-GMP and CUMS-IMC certified dried flower.

Medcolcanna has signed agreements with German-based Greenstein, as well as Berlin-based Cantourage.

The sales agreement with German-based Greenstein has a three-year term, with the possibility of extension, and establishes a minimum purchase of 1200 kg during the first year, 2000 kg during the second year and 2,500 kgs during the third year.

Its sales agreement with Cantourage for Germany and the UK has a five-year term, with the possibility of extension. The initial forecast presented by Cantourage establishes approximately 800 – 1000 Kgs for the first year.

Read more: Ugandan-grown medical cannabis reaches UK market

Cantourage will distribute the flower through its proprietary clinics and distribution in the UK and through its network of pharmacies in Germany. Medcolcanna has developed a new brand for distribution with Cantourage in UK and Germany, followed by Poland within the next few months.

Six Medcolcanna proprietary strains have been already registered with the German Narcotics agency, and the production will be based on supply from the Medcolcanna farm located near Bogota. Additionally, THC quotas have been granted by the Colombian Government and are in place with the first exports expected by October to November 2022.

CEO Felipe de la Vega commented: “It has being a long and difficult journey since we created the company. A market that we were trying to understand and anticipate but that was being created. Therefore, making decisions was more complex. 

“CBD market for extracts and isolates became very competitive with the US hemp farm bill affecting projections. The market for THC extracts is highly regulated, requires multiple certifications and a lot of investment, and still is a very small market compared with flower. 

“Now the approval of flower export has allowed us to really gain traction in Colombia supply, as a high quality, low-cost producer, and the result of it is the multiple contracts we have now in place and we continue to negotiate. Starting November 2022, we expect recurrent revenue with high margins and good profitability.

“This combined with internal decisions that have helped us to reduce our G&A and cash burn makes our company a sustainable and profitable target for investors and we are pretty confident that before the end of the year we will be in a completely different situation.

“We continue supplying internally medical formulations currently approximately 300 per month and growing at 15 per cent per month. Now we are really getting to an interesting point for the company, with a very clear path forward and the possibility to generate profits for our investors.”

Continue Reading
Sign up for the Cannabis Wealth newsletter

Recent Posts

[class^="wpforms-"]
[class^="wpforms-"]